Fatal and life-threatening ADRs associated with paliperidone palmitate: an observational study in the French pharmacovigilance database.
David BoelsJulien MahéA OlryA Citterio-QuentinJ MoragnyP JollietPublished in: Clinical toxicology (Philadelphia, Pa.) (2021)
PP-related ADRs leading to death or life-threatening events mainly presented with cardiorespiratory symptoms. Cardiac arrests and sudden unexpected deaths following initiation of PP treatment could be due to supratherapeutic drug concentrations. This study highlights the need to monitor blood concentrations of PP.Key pointsAdverse reactions to paliperidone palmitate can lead to death or life-threatening events.It is hypothesized that cardiac arrests and sudden unexpected deaths following initiation of paliperidone palmitate treatment could be due to supratherapeutic drug concentrations.This paper proposes the need to monitor blood concentrations of paliperidone palmitate in future studies.